Alpha Paradigm Partners LLC Acquires New Stake in Becton, Dickinson and Company (NYSE:BDX)

Alpha Paradigm Partners LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel reports. The firm acquired 1,126 shares of the medical instruments supplier’s stock, valued at approximately $274,000.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Acadian Asset Management LLC raised its position in Becton, Dickinson and by 53.6% during the 1st quarter. Acadian Asset Management LLC now owns 10,349 shares of the medical instruments supplier’s stock valued at $2,515,000 after purchasing an additional 3,612 shares in the last quarter. E Fund Management Co. Ltd. bought a new stake in Becton, Dickinson and during the 1st quarter valued at $224,000. Panagora Asset Management Inc. raised its position in Becton, Dickinson and by 1.3% during the 1st quarter. Panagora Asset Management Inc. now owns 10,807 shares of the medical instruments supplier’s stock valued at $2,628,000 after purchasing an additional 136 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Becton, Dickinson and by 0.3% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,340 shares of the medical instruments supplier’s stock valued at $8,836,000 after purchasing an additional 100 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in Becton, Dickinson and by 21.2% during the 1st quarter. Ensign Peak Advisors Inc now owns 156,168 shares of the medical instruments supplier’s stock valued at $37,971,000 after purchasing an additional 27,358 shares in the last quarter. Institutional investors own 84.25% of the company’s stock.

In related news, VP Thomas J. Spoerel sold 266 shares of the company’s stock in a transaction dated Friday, August 6th. The stock was sold at an average price of $242.30, for a total transaction of $64,451.80. Following the transaction, the vice president now directly owns 1,285 shares of the company’s stock, valued at approximately $311,355.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Claire Fraser sold 387 shares of the business’s stock in a transaction dated Wednesday, August 18th. The shares were sold at an average price of $251.58, for a total value of $97,361.46. The disclosure for this sale can be found here. Insiders have sold a total of 9,093 shares of company stock worth $2,330,578 over the last ninety days. 0.76% of the stock is currently owned by corporate insiders.

BDX opened at $239.84 on Thursday. The stock has a fifty day moving average price of $250.06 and a 200-day moving average price of $248.06. Becton, Dickinson and Company has a 12 month low of $226.15 and a 12 month high of $267.37. The firm has a market cap of $68.88 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.42 and a beta of 0.76. The company has a current ratio of 1.23, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Wednesday, August 4th. The medical instruments supplier reported $2.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.30. Becton, Dickinson and had a return on equity of 16.26% and a net margin of 9.72%. The company had revenue of $4.89 billion for the quarter, compared to analyst estimates of $4.51 billion. During the same period in the prior year, the company posted $2.20 EPS. The firm’s quarterly revenue was up 26.8% compared to the same quarter last year. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.9 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 30th. Investors of record on Thursday, September 9th were given a dividend of $0.83 per share. This represents a $3.32 annualized dividend and a yield of 1.38%. The ex-dividend date of this dividend was Wednesday, September 8th. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lowered Becton, Dickinson and from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $276.93 to $265.00 in a research report on Friday, August 6th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “strong sell” rating and set a $208.00 target price for the company. in a research report on Monday, October 4th. Finally, SVB Leerink decreased their target price on Becton, Dickinson and from $260.00 to $250.00 and set a “market perform” rating for the company in a research report on Friday, August 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and has an average rating of “Hold” and an average target price of $266.33.

Becton, Dickinson and Profile

Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

Featured Article: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.